TY - JOUR
T1 - Dydrogesterone
T2 - pharmacological profile and mechanism of action as luteal phase support in assisted reproduction
AU - Griesinger, Georg
AU - Tournaye, Herman
AU - Macklon, Nick
AU - Petraglia, Felice
AU - Arck, Petra
AU - Blockeel, Christophe
AU - van Amsterdam, Peter
AU - Pexman-Fieth, Claire
AU - Fauser, Bart Cjm
N1 - Copyright © 2018 Reproductive Healthcare Ltd. Published by Elsevier Ltd. All rights reserved.
PY - 2019/2
Y1 - 2019/2
N2 - The pharmacological and physiological profiles of progestogens used for luteal phase support during assisted reproductive technology are likely to be important in guiding clinical choice towards the most appropriate treatment option. Various micronized progesterone formulations with differing pharmacological profiles have been investigated for several purposes. Dydrogesterone, a stereoisomer of progesterone, is available in an oral form with high oral bioavailability; it has been used to treat a variety of conditions related to progesterone deficiency since the 1960s and has recently been approved for luteal phase support as part of an assisted reproductive technology treatment. The primary objective of this review is to critically analyse the clinical implications of the pharmacological and physiological properties of dydrogesterone for its uses in luteal phase support and in early pregnancy.
AB - The pharmacological and physiological profiles of progestogens used for luteal phase support during assisted reproductive technology are likely to be important in guiding clinical choice towards the most appropriate treatment option. Various micronized progesterone formulations with differing pharmacological profiles have been investigated for several purposes. Dydrogesterone, a stereoisomer of progesterone, is available in an oral form with high oral bioavailability; it has been used to treat a variety of conditions related to progesterone deficiency since the 1960s and has recently been approved for luteal phase support as part of an assisted reproductive technology treatment. The primary objective of this review is to critically analyse the clinical implications of the pharmacological and physiological properties of dydrogesterone for its uses in luteal phase support and in early pregnancy.
U2 - 10.1016/j.rbmo.2018.11.017
DO - 10.1016/j.rbmo.2018.11.017
M3 - Scientific review articles
C2 - 30595525
SN - 1472-6483
VL - 38
SP - 249
EP - 259
JO - Reproductive BioMedicine Online
JF - Reproductive BioMedicine Online
IS - 2
ER -
